that a majority of GIST are associated with activating, somatic, mutually exclusive mutations of 2 genes , KIT and PDGFRA (plateletderived growth factor receptor-alpha), and an overexpression and activation of the oncoproteins KIT and PDGFR. Advances in the understanding of molecular pathogenesis of GIST have resulted in the development of a treatment modality which has become a model for targeted therapy in oncology. Imatinib mesylate has revolutionized the therapy of advanced GIST and was the first effective, worldwide approved nonsurgical treatment in inoperable and/ or metastatic cases, and currently in adjuvant therapy. The treatment of choice in primary, resectable, localized GIST is radical surgery with negative margins. However, the microscopic status of surgical margins is controversial and contrary to other sarcomas, GIST local recurrences occur rarely.
Introduction
Gastrointestinal stromal tumors (GIST) comprise a heterogeneous group of mesenchymal tumors and the most common sarcomas of the gastrointestinal tract. Radical surgery is the treatment of choice for primary, resectable, localized GIST, but the majority of GISTs is associated with some risk of recurrence, and approximately 40-50% of patients relapse after potentially curative resections, mostly in the form of metastatic disease [1] [2] [3] . Understanding the molecular mechanisms of their pathogenesis demonstrated fied classification system based on 4 prognostic factors (tumor size, site, mitotic count), including the presence of tumor rupture [9] [10] [11] . It seems also rather obvious that patients with resectable primary GIST who undergo R0 resection have significantly longer survival that those after incomplete (especially macroscopic) resection [2, 12] ; however, this may be related to the primary characteristic of a more aggressive and advanced tumor than mechanistic effect of microscopic residual disease.
The aim of this review based on systematic search of published literature is to discuss the importance of achieving macroscopically and microscopically tumor-free margins in GIST and definition of margins, as well as the possible impact of perioperative therapy.
Assessment of Primary GIST Margins
The correct interpretation of the pathological margins after GIST resection may be challenging and should be performed by an experienced sarcoma pathologist. GIST may occur in all localizations in the gastrointestinal tract. The first step is a proper orientation of the specimen, which should be well marked and described by the surgeon. The margin's evaluation can be affected by contraction of tumor, bowel/stomach wall as well as fixation of the specimen after resection and tissue preparation. The suspicion of microscopically positive R1 resection margin should be carefully evaluated, because it does not always mean incomplete resection due to false-positive assessment based on improper orientation of specimen, tissue contraction, or encapsulation after resection. It is necessary to record if there was a tumor rupture (to the peritoneal cavity) during the operation. To correctly interpret the microscopic image of the removed tumor and establish the margins of resection, it should be considered that GIST is a tumor growing under the mucosa [13] , and mucosal margin from the lumen of the gastrointestinal tract is not clinically meaningful (as GIST may be often ulcerated). The margins of clinically importance are ( fig. 1-3 ): (1) from the peritoneal cavity side -the tumor pseudocapsule covered by one layer of serosa may constitute this margin and, if intact, it is a sufficient one, and this is a natural limit as you cannot achieve a wider margin here ( fig. 4) , if it is disrupted it implies the tumor rupture; (2) lateral margins or proximal and distal resection margins of the stomach/intestine wall which are suggested to be at least 1 cm. In this area, the width of the excision should be verified. These margins determine whether a R0, R1, or R2 resection has been performed.
Principles of GIST Surgery
Surgery is the mainstay and the only potentially curative treatment for primary localized GIST. The recommended approach is R0 resection with wide margins of about 1-2 cm ( fig. 4 ). Gentle handling is also very important to avoid tumor rupture. Routine lymphadenectomy is not recommended unless there is no suspicion of intraoperative lymph node metastasis. Wide wedge-like excision is recommended, but in some cases, partial or complete gastrectomy may be necessary due to the location (pylorus or gastroesophageal junction) or size of the tumor, although several studies did not confirm any benefits of extended surgery for gastric GIST beyond a local excision [14] . Nondisruptive surgical techniques must be used in all cases of GIST, especially those with large cystic or necrotic components. Tumor enucleation is considered insufficient because it may leave tumor cells behind a pseudocapsule; it is also considered as tumor rupture [15] . Nishimura et al. [16] found 33% incidence of local or peritoneal recurrence in tumors which were incidentally enucleated during surgical resection.
In the case of initially advanced, marginally resectable tumors or with risk of mutilating surgery, the neoadjuvant imatinib should be considered, especially in high-risk patients to reduced extent of surgery and the risk of tumor rupture during operation. When GIST are adherent to contiguous organs, en-bloc resection of the tumor and adherent structures should be considered [17, 18] .
Laparoscopy/Endoscopy in the Treatment of GIST
The currently widely discussed clinical problem is the use of minimally invasive laparoscopic and endoscopic surgery for the removal of primary GIST. There are many papers on the safety of laparoscopic resection; however, most often they refer only to gastric GIST. The achieved oncological results are comparable to open surgery [19] [20] [21] [22] . Currently, laparoscopic resection is permissible in tumors below 10 cm in maximal diameter and when the risk of local recurrence is low even after R1 resection; however, the size limits of tumors are constantly shifted. In the case of laparoscopic treatment, similar rules apply as in the case of open surgery plus it is necessary to remember to be gentle during the operation (extra care while manipulating because GIST are soft and fragile) ( fig. 5 ) . Moreover, the tumor should be removed from the peritoneal cavity in an extraction bag to avoid contamination of the abdominal cavity with cancer cells (intraperitoneal seeding). If not, this immediately changes the patient's outcome and shifts the patient into a high-risk group. Tumor disruption must be avoided at all costs; tumor enucleation leaves a tumor-seeded pseudocapsule behind and is considered insufficient.
In small (low-risk) GISTs, attempts are made to remove them endoscopically, however, often it is not possible to obtain a wide R0 resection but even in the case of R1 resection, the prognosis of patients is comparable. Moreover, only patients with small lowrisk well-defined tumors should be considered eligible for endoscopic GIST removal in one part. R1 resection is more frequent in the endoscopic resection but the recurrence rate in some studies is as low as 3% and is therefore not much different from surgical re- 350 section [13, 23] . Joo et al. [23] reported an R0 resection rate of 25.6% in the endoscopy group, whereas it was 85.0% in the surgery group (p < 0.001). In the endoscopy group, 50.0% of resected tumors belonged to a very low-risk group, whereas 35.0 and 30.0% belonged to the low-risk and high-risk surgery group (p < 0.001), respectively. Nevertheless, with 45.5-month follow-up, the recurrence rate was not significantly different between these 2 groups (2.2 vs. 5.0%; p = 0.586).
Margins and Risk of Recurrence
The impact of microscopic positivity on the patients' outcomes was not studied systematically and major series ( table 1 ) show inconsistent data [2, [24] [25] [26] . It is currently doubtful that a positive macroscopic surgical margin status (R2 resection) is associated with poor disease-specific survival in GIST [25] [26] [27] . Although in sarcoma surgery it is believed that achieving R0 resection is one of the most important factors predicting good prognosis, the ESMO guidelines state that 'when R0 surgery implies major functional sequelae, a preoperative medical treatment has not helped or cannot be exploited, the decision can be shared with patient to accept possible R1 margins' [14] . Microscopically positive margins are the most acceptable for low-risk lesions lacking the formal demonstration of an association of R1 surgery with poorer overall survival [28] . Several major published series in primary GIST analyzed only the term complete macroscopic resection [12, 27, 29] , whereas others focused on R0 resections [30] [31] [32] as the desired standard of care in the surgical treatment of GIST. Some studies showed that microscopic (positive or negative) surgical margin status has no influence on a patient's survival/tumor recurrence in GIST [12, 24, 27] . The published series including the assessment of microscopically positivity of margins are relatively small, and they included a high number of large and high-grade GIST, in which even complete resection does not seem to avoid tumor recurrence and shorter patient survival due to a natural course of disease. Other studies demonstrate that microscopically negative surgical margin status (R0 resection) has an important impact on the prognosis in GIST [2, 30, 31, 33, 34 ] . An analysis of 79 cases by a Swedish group reported that local/peritoneal recurrences were diagnosed in a significantly lower percentage of 2 out of 39 cases with wide margins (at least 2 cm width of margin), in 7 out of 22 cases with marginal margins (less than 2 cm), and in 13 out of 18 cases with intralesional surgery. Multivariate evaluation confirmed that the surgical margin remained an independent significant predictor for risk for recurrence. Patients with R0 surgery showed a longer time to peritoneal recurrence and better recurrence-free and disease-specific survival as compared to those with R1 resection. One study based on the analysis of data from the prospective clinical trials ACO-SOG Z9000 and Z9002 concluded that tumor size and not a microscopically tumor-positive margin was associated with disease-specific survival [24] . DeMatteo et al. [27] suggested that treatment failure, particularly in large, high-risk GIST, occurs independently of the microscopic margins of resection. In GIST, which sometimes extend through the serosa of the bowel or stomach wall, cells may be intraperitoneally bashed from the tumor surface, and this may be related to the mechanism of disease recurrence in the form of intra-abdominal and not local recurrences. Crosby et al. [35] reported that in 10 out of 24 patients with negative microscopic margins in primary resection of small bowel GIST and negative lateral margins, peritoneal metastases were detected, which may support this theory. In a systematic review and meta-analysis evaluating the prognostic role of microscopically positive margins for primary GIST [36] , which was based on 12 studies comprising 1,985 patients, it was concluded that a microscopically positive margin may have significant impact on disease-free survival (HR (hazard ratio) 1.6; p = 0.09) without influence on overall survival (HR 1.4).
All available data indicate unequivocally that an important, negative factor influencing the recurrences is tumor perforation or intraperitoneal bleeding [9, 11, [37] [38] [39] . Tumor rupture -spontaneous or iatrogenic -may change GIST from low-risk to high-risk or micro-metastatic. In the study performed by the authors' present group [2] , the estimated 5-year relapse-free survival rate was only 17% in the group of patients with ruptured tumor as compared to 55% in the rest of the patients (p < 0.00001), and it was a statistically significant independent prognostic factor. The postoperative course of patients with tumor rupture either preoperatively or during resection was similar to that of patients with macroscopic incomplete R2 resection, with shorter overall survival. In the study by McCarter et al. [24] , the risk of recurrence within the R1 group appeared to be driven largely by the presence of tumor rupture or intraperitoneal bleeding. The 3-year relapse-free survival for R1 351 patients with tumor rupture was 60 versus 80% in R1 patients without rupture. Excluding all patients with documented tumor rupture resulted in the same outcomes for R1 and R0 patients. Hølme-bakk et al. [39] tried to further define the clinical significance of tumor perforation and they reported that recurrence rates after primary tumor resection were increased after major tumor ruptures defined as tumor spillage, tumor fracture or piecemeal resection, bowel perforation at the tumor site, blood-tinged ascites, microscopic tumor infiltration into an adjacent organ, and open surgical biopsy, but not after minor tumor perforations (peritoneal tumor penetration, iatrogenic peritoneal laceration, and microscopically involved margins).
Influence of Perioperative Therapy
Historically, surgery was the only effective therapy in primary GIST. Taking into account that therapy with tyrosine kinase inhibitors is highly efficient in metastatic GIST, locally advanced GIST may also potentially benefit from neoadjuvant treatment with imatinib through a decrease in size and vulnerability [40] [41] [42] . Preoperative therapy devitalizes tumor facilitating tumor resection leading to less morbidity and such strategy is supported by ESMO and NCCN recommendations. According to some studies, the risk of intraperitoneal bleeding/tumor perforation may be decreased after neoadjuvant imatinib in high-risk tumors [41, 43] , enabling complete resection, increasing integrity of pseudocapsule, improving quality of margins, and increasing chances for relapse-free survival.
Currently, after resection of GIST considered at high risk of relapse, 36 months of adjuvant treatment with imatinib is the standard therapeutic approach. It seems that this strategy could attenuate the risk of recurrence for primary GIST after R1 resection. The results of a meta-analysis indicated that adjuvant imatinib therapy can decrease the risk of recurrence in primary GIST after R1 resection (HR 1.3), and in the group of patients after R1 resection without adjuvant therapy disease-free survival remained poorer [36] . Nevertheless, according to the analysis of databases of two adjuvant trials, i.e. SSG XVIII and ACOSOG Z9001, tumor rupture remains significant for unfavorable recurrence-free survival in population of GIST patients treated with adjuvant imatinib [44] .
Conclusions
To summarize, radical surgical excision of primary localized GIST is the standard of care. The published series underline that resection with microscopically negative margins increases the chances for better relapse-free survival, although this effect in lowrisk tumors is uncertain as is the influence on overall survival. In case of primary resection with positive margins by histopathological assessment, a careful reevaluation should be undertaken by an experienced pathologist to exclude false-positive results, and the decision about possible reoperation should be individualized, taking into account a balance between the risk of reoperation, the possible benefits, and the aggressiveness of the primary tumor. Intraperitoneal tumor rupture has the most significant consequences, and shifting primary curable GIST to high-risk or micro-metastatic disease and iatrogenic perforation should always be avoided. Neoadjuvant imatinib therapy in selected cases may facilitate R0 resection and render the tumor less fragile and hypervascular, decreasing the risk of tumor rupture or intraoperative bleeding. The available data indicate that adjuvant imatinib treatment in GIST is effective in alleviating the effect of R1 primary tumor resection.
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